Delta-9-cis-tetrahydrocannabinol molecule, CIS THC molecule

Delta-9-cis-tetrahydrocannabinol (cisTHC) is a synthetic cannabinoid. It belongs to the class of cannabinols discovered through the actions of humans and by research. These compounds don’t occur naturally in the cannabis plant. Synthetic compounds are often products of certain chemical functions or reactions between two cannabinoids or cannabinols and their environment. The degradation of some cannabinols leads to the formation of other compounds. During the process of isolating a certain compound, some other compounds may be derived.

Cannabidiols were discovered in 1940 by British scientist Robert Cahn. In 1986, a group of scientists under R.K. Razdan analyzed the structural-activity relationship (SAR) of cannabinoids. We don’t know who discovered the cis-THC compound, although the earliest mention of the compound was in 2017.

The formation of cis-THC is purely synthetic and doesn’t occur naturally in the cannabis plant. Although in name, the cis-THC compound sounds similar to the THC compound derived from the CBN and CGBV mother compounds, they are not be mistaken for each other. The compound cis-THC is said to have no similarity to the THC family hence its un-categorization and its miscellaneous compound tag. Rather, its structure similarity is with compounds like cannabrichromene, synhexyl, dibenzo(b,d)pyran-6-methanol, and some others. In its chemical structure, cis-THC has an HBD count of 1, HBA of 2, and RB count of 4. With a topological surface area of 29.5A2, a heavy atom count of 23, its property complexity value is 439.

Owing to its small quantity and pervasive nature, cis-THC is one of the unique compounds of the marijuana plant. Without research and clinical trials, there is no knowing what this compound can do. The future of the compound is very much tied to the conclusion of the debate around the cannabis plant currently happening in the world. With the US leading the legalization game, we are hoping that other countries will follow in the struggle to allow the use of the compound and plant in the world of medicine.


Cannabinoids are known to bond with the human receptors available in the human body.  These receptors are found to be encoded with protein like constituent and found to be tied to the body’s immune system. Cannabidiols combine with these receptors to perform its functions. Cis-THC hasn’t gone through clinical trials and tests for us to know how it functions at these receptor points. To know more about how the compound works, we will have to wait until these trials, research, and experiments are done.


The cannabidiols are a promising compound as regards the scope of therapy. We have some compounds that are psychoactive, some that act as nerve blockers, some that help with diarrhea, insomnia, etc. The cis-THC compound will have its own features and benefits in the treatment of ailments and diseases; we just need the research and trials to kick off.


  1. It has a molar mass of 314.5 g/mol.
  2. Its chemical formula is C21H30O2.
  3. Its IUPAC name is (6aS,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol.


National Center for Biotechnology Information. PubChem Compound Summary for CID 12831993, delta-9-cis-Tetrahydrocannabinol, (-)-. 

Prandi C, Blangetti M, Namdar D, Koltai H. Structure-Activity Relationship of Cannabis Derived Compounds for the Treatment of Neuronal Activity-Related Diseases. Molecules. 2018 Jun 25;23(7):1526. doi: 10.3390/molecules23071526. PMID: 29941830; PMCID: PMC6099582.

Uliss DB, Dalzell HC, Handrick GR, Howes JF, Razdan RK. Hashish. Importance of the phenolic hydroxyl group in tetrahydrocannabinols. J Med Chem. 1975 Feb;18(2):213-ss5. doi: 10.1021/jm00236a025. PMID: 1120991.

Leave a Comment

Your email address will not be published. Required fields are marked *